Brigatinib-induced tuberculosis reactivation: A case report
Brigatinib is a novel potent tyrosine kinase inhibitor as third-generation therapy for anaplastic lymphoma kinase (ALK) rearrangement positive non-small cell lung cancer (NSCLC). Clinical trials show that brigatinib is potent choice of treatment for the first line and further lines of treatment of A...
Gespeichert in:
| Veröffentlicht in: | Current problems in cancer 2021-12, Vol.45 (6), p.100738-100738, Article 100738 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 100738 |
|---|---|
| container_issue | 6 |
| container_start_page | 100738 |
| container_title | Current problems in cancer |
| container_volume | 45 |
| creator | Keş, Volkan Sütcüoğlu, Osman Gürler, Fatih Yazıcı, Ozan Özet, Ahmet |
| description | Brigatinib is a novel potent tyrosine kinase inhibitor as third-generation therapy for anaplastic lymphoma kinase (ALK) rearrangement positive non-small cell lung cancer (NSCLC). Clinical trials show that brigatinib is potent choice of treatment for the first line and further lines of treatment of ALK rearranged NSCLC with highly potent anti-tumor effect on brain metastasis. The adverse effects of brigatinib are tolerable and managable. However, there is limited data about effects on immune system. The most possible serious adverse effect of brigatinib on immune system might be brigatinib associated grade 3-4 lymphopenia. Here we report a brigatinib-induced tuberculosis reactivation patient who is using third-line brigatinib for metastatic NSCLC and have partial response. |
| doi_str_mv | 10.1016/j.currproblcancer.2021.100738 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2515068072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0147027221000453</els_id><sourcerecordid>2515068072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-7ac599be30dfacca17e793509bc4a80ae7f5973851ee5632a46182f4991e4a6b3</originalsourceid><addsrcrecordid>eNqNkD1PwzAQhi0EoqXwF1AXJJYUf8RxDGIoFRSkSiwwW87lglylSbGTSvx7XKUwMDGd5HveO99DyBWjM0ZZdrOeQe_91rdFDbYB9DNOOYs9qkR-RMZMCplkIpXHZExZqhLKFR-RsxDWlDKumTwlIyHyTDGZjsndg3cftnONKxLXlD1gOe36Aj30dRtcmHq00LldRNrmdjqfgg0YH7et787JSWXrgBeHOiHvT49vi-dk9bp8WcxXCYhcd4myILUuUNCysgCWKVRaSKoLSG1OLapK6vh5yRBlJrhNM5bzKtWaYWqzQkzI9TA3Xv3ZY-jMxgXAurYNtn0wXDJJs5wqHtH7AQXfhuCxMlvvNtZ_GUbN3p9Zmz_-zN6fGfzF_OVhVV9ssPxN_wiLwHIAMB68czEewGGcUzqP0Jmydf9c9Q28eIrc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2515068072</pqid></control><display><type>article</type><title>Brigatinib-induced tuberculosis reactivation: A case report</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Keş, Volkan ; Sütcüoğlu, Osman ; Gürler, Fatih ; Yazıcı, Ozan ; Özet, Ahmet</creator><creatorcontrib>Keş, Volkan ; Sütcüoğlu, Osman ; Gürler, Fatih ; Yazıcı, Ozan ; Özet, Ahmet</creatorcontrib><description>Brigatinib is a novel potent tyrosine kinase inhibitor as third-generation therapy for anaplastic lymphoma kinase (ALK) rearrangement positive non-small cell lung cancer (NSCLC). Clinical trials show that brigatinib is potent choice of treatment for the first line and further lines of treatment of ALK rearranged NSCLC with highly potent anti-tumor effect on brain metastasis. The adverse effects of brigatinib are tolerable and managable. However, there is limited data about effects on immune system. The most possible serious adverse effect of brigatinib on immune system might be brigatinib associated grade 3-4 lymphopenia. Here we report a brigatinib-induced tuberculosis reactivation patient who is using third-line brigatinib for metastatic NSCLC and have partial response.</description><identifier>ISSN: 0147-0272</identifier><identifier>EISSN: 1535-6345</identifier><identifier>DOI: 10.1016/j.currproblcancer.2021.100738</identifier><identifier>PMID: 33867154</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - genetics ; Adenocarcinoma - pathology ; Anaplastic Lymphoma Kinase - drug effects ; Bone Neoplasms - secondary ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Humans ; Immunodeficiency ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Lymphopenia ; Male ; Middle Aged ; Organophosphorus Compounds - adverse effects ; Organophosphorus Compounds - therapeutic use ; Protein Kinase Inhibitors ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Tuberculosis - chemically induced ; Tyrosine kinase inhibitor</subject><ispartof>Current problems in cancer, 2021-12, Vol.45 (6), p.100738-100738, Article 100738</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-7ac599be30dfacca17e793509bc4a80ae7f5973851ee5632a46182f4991e4a6b3</citedby><cites>FETCH-LOGICAL-c389t-7ac599be30dfacca17e793509bc4a80ae7f5973851ee5632a46182f4991e4a6b3</cites><orcidid>0000-0003-3835-2741 ; 0000-0003-0023-5793</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0147027221000453$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33867154$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Keş, Volkan</creatorcontrib><creatorcontrib>Sütcüoğlu, Osman</creatorcontrib><creatorcontrib>Gürler, Fatih</creatorcontrib><creatorcontrib>Yazıcı, Ozan</creatorcontrib><creatorcontrib>Özet, Ahmet</creatorcontrib><title>Brigatinib-induced tuberculosis reactivation: A case report</title><title>Current problems in cancer</title><addtitle>Curr Probl Cancer</addtitle><description>Brigatinib is a novel potent tyrosine kinase inhibitor as third-generation therapy for anaplastic lymphoma kinase (ALK) rearrangement positive non-small cell lung cancer (NSCLC). Clinical trials show that brigatinib is potent choice of treatment for the first line and further lines of treatment of ALK rearranged NSCLC with highly potent anti-tumor effect on brain metastasis. The adverse effects of brigatinib are tolerable and managable. However, there is limited data about effects on immune system. The most possible serious adverse effect of brigatinib on immune system might be brigatinib associated grade 3-4 lymphopenia. Here we report a brigatinib-induced tuberculosis reactivation patient who is using third-line brigatinib for metastatic NSCLC and have partial response.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - pathology</subject><subject>Anaplastic Lymphoma Kinase - drug effects</subject><subject>Bone Neoplasms - secondary</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Humans</subject><subject>Immunodeficiency</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Lymphopenia</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Organophosphorus Compounds - adverse effects</subject><subject>Organophosphorus Compounds - therapeutic use</subject><subject>Protein Kinase Inhibitors</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Tuberculosis - chemically induced</subject><subject>Tyrosine kinase inhibitor</subject><issn>0147-0272</issn><issn>1535-6345</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkD1PwzAQhi0EoqXwF1AXJJYUf8RxDGIoFRSkSiwwW87lglylSbGTSvx7XKUwMDGd5HveO99DyBWjM0ZZdrOeQe_91rdFDbYB9DNOOYs9qkR-RMZMCplkIpXHZExZqhLKFR-RsxDWlDKumTwlIyHyTDGZjsndg3cftnONKxLXlD1gOe36Aj30dRtcmHq00LldRNrmdjqfgg0YH7et787JSWXrgBeHOiHvT49vi-dk9bp8WcxXCYhcd4myILUuUNCysgCWKVRaSKoLSG1OLapK6vh5yRBlJrhNM5bzKtWaYWqzQkzI9TA3Xv3ZY-jMxgXAurYNtn0wXDJJs5wqHtH7AQXfhuCxMlvvNtZ_GUbN3p9Zmz_-zN6fGfzF_OVhVV9ssPxN_wiLwHIAMB68czEewGGcUzqP0Jmydf9c9Q28eIrc</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Keş, Volkan</creator><creator>Sütcüoğlu, Osman</creator><creator>Gürler, Fatih</creator><creator>Yazıcı, Ozan</creator><creator>Özet, Ahmet</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3835-2741</orcidid><orcidid>https://orcid.org/0000-0003-0023-5793</orcidid></search><sort><creationdate>202112</creationdate><title>Brigatinib-induced tuberculosis reactivation: A case report</title><author>Keş, Volkan ; Sütcüoğlu, Osman ; Gürler, Fatih ; Yazıcı, Ozan ; Özet, Ahmet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-7ac599be30dfacca17e793509bc4a80ae7f5973851ee5632a46182f4991e4a6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - pathology</topic><topic>Anaplastic Lymphoma Kinase - drug effects</topic><topic>Bone Neoplasms - secondary</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Humans</topic><topic>Immunodeficiency</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Lymphopenia</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Organophosphorus Compounds - adverse effects</topic><topic>Organophosphorus Compounds - therapeutic use</topic><topic>Protein Kinase Inhibitors</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Tuberculosis - chemically induced</topic><topic>Tyrosine kinase inhibitor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Keş, Volkan</creatorcontrib><creatorcontrib>Sütcüoğlu, Osman</creatorcontrib><creatorcontrib>Gürler, Fatih</creatorcontrib><creatorcontrib>Yazıcı, Ozan</creatorcontrib><creatorcontrib>Özet, Ahmet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current problems in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Keş, Volkan</au><au>Sütcüoğlu, Osman</au><au>Gürler, Fatih</au><au>Yazıcı, Ozan</au><au>Özet, Ahmet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brigatinib-induced tuberculosis reactivation: A case report</atitle><jtitle>Current problems in cancer</jtitle><addtitle>Curr Probl Cancer</addtitle><date>2021-12</date><risdate>2021</risdate><volume>45</volume><issue>6</issue><spage>100738</spage><epage>100738</epage><pages>100738-100738</pages><artnum>100738</artnum><issn>0147-0272</issn><eissn>1535-6345</eissn><abstract>Brigatinib is a novel potent tyrosine kinase inhibitor as third-generation therapy for anaplastic lymphoma kinase (ALK) rearrangement positive non-small cell lung cancer (NSCLC). Clinical trials show that brigatinib is potent choice of treatment for the first line and further lines of treatment of ALK rearranged NSCLC with highly potent anti-tumor effect on brain metastasis. The adverse effects of brigatinib are tolerable and managable. However, there is limited data about effects on immune system. The most possible serious adverse effect of brigatinib on immune system might be brigatinib associated grade 3-4 lymphopenia. Here we report a brigatinib-induced tuberculosis reactivation patient who is using third-line brigatinib for metastatic NSCLC and have partial response.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33867154</pmid><doi>10.1016/j.currproblcancer.2021.100738</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3835-2741</orcidid><orcidid>https://orcid.org/0000-0003-0023-5793</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0147-0272 |
| ispartof | Current problems in cancer, 2021-12, Vol.45 (6), p.100738-100738, Article 100738 |
| issn | 0147-0272 1535-6345 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2515068072 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Anaplastic Lymphoma Kinase - drug effects Bone Neoplasms - secondary Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Humans Immunodeficiency Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Lymphopenia Male Middle Aged Organophosphorus Compounds - adverse effects Organophosphorus Compounds - therapeutic use Protein Kinase Inhibitors Pyrimidines - adverse effects Pyrimidines - therapeutic use Tuberculosis - chemically induced Tyrosine kinase inhibitor |
| title | Brigatinib-induced tuberculosis reactivation: A case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T03%3A05%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brigatinib-induced%20tuberculosis%20reactivation:%20A%20case%20report&rft.jtitle=Current%20problems%20in%20cancer&rft.au=Ke%C5%9F,%20Volkan&rft.date=2021-12&rft.volume=45&rft.issue=6&rft.spage=100738&rft.epage=100738&rft.pages=100738-100738&rft.artnum=100738&rft.issn=0147-0272&rft.eissn=1535-6345&rft_id=info:doi/10.1016/j.currproblcancer.2021.100738&rft_dat=%3Cproquest_cross%3E2515068072%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2515068072&rft_id=info:pmid/33867154&rft_els_id=S0147027221000453&rfr_iscdi=true |